Jump to Main Content


ASH Selects 11 Fellows for Research Award to Support Careers in Academic Hematology

(WASHINGTON, July 17, 2017) – The American Society of Hematology (ASH) today announced the names of 11 outstanding fellows selected to receive the 2017 ASH Research Training Award for Fellows (RTAF), a year-long program that aims to encourage careers in academic hematology by providing protected research time during training.

Each RTAF awardee will receive $70,000 to support a hematology research project throughout the program’s duration, from July 1, 2017, to June 30, 2018. The majority of the award money will support the recipient’s salary, with a percentage to be used for research supplies and travel to related scientific meetings, including the ASH annual meeting. Awards are targeted to two groups of researchers based on experience: a Junior Investigator award for second- and third-year fellows, and a Senior Investigator award for fourth- and fifth-year fellows.

“It’s often difficult to find sufficient time to conduct high-quality research during training,” said ASH President Kenneth C. Anderson, MD, of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center at Dana-Farber Cancer Institute in Boston. “By supporting protected time for scientific exploration for these talented fellows, ASH is giving them the opportunity to conduct quality research, which will lead to academic appointments and future research funding.”

The 2017 ASH Research Training Award for Fellows recipients and their research topics are:

Recipient Research Topics
Akshay Sharma, MBBS
University of Tennessee
Knoxville, TN
Enhancer dissection to understand fetal hemoglobin regulation
Allison Remiker, MD
Cincinnati Children's Hospital Medical Center
Cincinnati, OH
Mechanisms linking fibrin(ogen) structure/function to tumor metastasis
Ami Patel, MD
University of Utah
Salt Lake City, UT
Bone marrow stroma-based mechanisms of resistance in FLT3-ITD+ acute myeloid leukemia
Hojun Li, MD, PhD
Boston Children's Hospital
Boston, MA
Deciding cell fate in hematopoiesis: asymmetric cell division in erythropoiesis as a model
Kandace Gollomp, MD
University of Pennsylvania
Philadelphia, PA
HITing into the NET: A proposed role for neutrophils and NETs in the pathogenesis of heparin-induced thrombocytopenia
Kelly Bolton, MD, PhD
Memorial Sloan-Kettering Cancer Center/New York Presbyterian
New York, NY
The impact of oncologic therapy on clonal hematopoiesis and secondary leukemia
Pamela Sung, MD, PhD
University of Pennsylvania
Philadelphia, PA
Understanding mechanisms of primary resistance to targeted therapy in FLT3 mutated acute myeloid leukemia
Ryan Woods, MD
Wake Forest University School of Medicine
Winston-Salem, NC
Development of a nanobody against wild-type and mutant calreticulin
Sarah Buckley, MD
Fred Hutchinson Cancer Research Center
Seattle, WA
Disease-specific measurement of quality of life and adverse events in patients with acute myeloid leukemia
Seongseok Yun, MD, PhD
University of South Florida, Morsani College of Medicine
Tampa, FL
The role of c-MYC and TFEB in the acute myeloid leukemia leukemogenesis
Tian Yi Zhang, MD, PhD
Stanford University
Stanford, CA
Dissecting the mechanism of bone marrow failure in acute myeloid leukemia

The American Society of Hematology (www.hematology.org) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 50 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. ASH publishes Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field, which is available weekly in print and online. In 2016, ASH launched Blood Advances (www.bloodadvances.org), an online, peer-reviewed open-access journal.

Sara Khalaf, American Society of Hematology
[email protected]; 202-552-4925